Alternatives
A GlobalData alternative — when the question is one asset.
GlobalData answers questions about markets. Prognyx answers questions about your competitors. Those are different jobs, and only one of them can be bought by the month.
People look for a GlobalData alternative when they realise they bought a market-research capability to solve a competitor-watching problem. The platform is broad and the forecasting is its genuine centre of gravity — but a clinical-stage company with one lead asset rarely needs a market model. It needs to know what the two companies ahead of it did last month.
What GlobalData actually is
GlobalData's Pharma Intelligence Center is an integrated data and analysis platform covering pipeline and marketed drugs, clinical trials, investigators and sites, deals and company profiles, patents, pricing and reimbursement, and epidemiology with disease forecasting. It layers analyst commentary and a large report library on top, along with predictive models — likelihood of approval, phase transition success rates — and it sits inside a house that covers many industries beyond pharmaceuticals.
Its strongest suit is breadth with quantitative framing: if the question is how large an indication will be in 2032, which markets carry the epidemiology, and what a comparable asset's approval odds look like against a historical base rate, that is what the platform is built to answer. Nothing here disputes that.
What Prognyx is
Prognyx is a delivered oncology competitive-intelligence service. No login and no query: the watch runs continuously against your competitive set, and when something moves you get a brief explaining what happened, what it means and what to do — every claim traced to the primary record.
| Dimension | GlobalData | Prognyx |
|---|---|---|
| What you buy | A subscription to the Pharma Intelligence Center — drugs, trials, deals, patents, pricing, epidemiology and forecasts in one platform | A person’s output — a written read on your competitive set |
| Core strength | Market sizing, epidemiology and forecasting, with analyst commentary and report library | Deciding what a competitor’s move does to your asset |
| Analytics | Predictive models such as likelihood of approval and phase transition success rates | A stated argument with its reasoning shown, not a score |
| Sector scope | Pharma plus many other industries the same house covers | Oncology only |
| Who asks the questions | You, inside the platform | Prognyx, continuously, without being asked |
| Mode | Pull, with configurable alerts | Push — the brief arrives when something moves |
| Seats | Priced per seat and per module | Not applicable |
| Contract shape | Annual enterprise subscription, demo-gated | Month to month, written scope, no lock-in |
| Accountability for a wrong read | Yours | One named analyst, publicly |
| Published pricing | Not published | Published — from $2,000/mo |
When GlobalData is the better buy
- You need epidemiology and market forecasts. Patient-population modelling and revenue forecasting are a real specialism and Prognyx has nothing equivalent. For a fundraise deck or a licensing valuation, buy the model.
- You need pricing, reimbursement or HTA intelligence. Entirely outside Prognyx's scope.
- You need a defensible third-party number. Boards and investors sometimes want a citable market figure from a recognised research house. A brief is an argument, not a market size.
- Your remit is broader than one therapeutic area — several indications, devices, diagnostics, or work outside healthcare.
- You have someone to run it. The platform rewards a user who knows what to ask and has time to ask it.
When Prognyx is the better buy
- The question is "what did our competitors just do". That is a watching problem, not a modelling problem, and it recurs weekly rather than quarterly.
- You need reasoning you can inspect. A likelihood-of-approval score is a useful prior; it does not tell you why a rival's hazard ratio was reported without a p-value or what that implies for your own filing strategy. Prognyx shows the argument and links the source.
- Nobody will log in. A pull platform only works if someone reliably pulls. The move that hurts is the one nobody thought to look for that week.
- You want a forwardable artefact. A brief goes to your board or your co-founder as-is.
- The budget is real. Prognyx publishes its floor: from $2,000/mo, scoped to your pipeline.
The cost question, honestly
GlobalData does not publish list pricing for the Pharma Intelligence Center; access is arranged through a demo and a quote. This page will not guess at a figure. Structurally it is an annual enterprise subscription priced by module and seat, which is a shape built for organisations spreading the cost across teams.
Using both
They answer different questions and there is no conflict in holding both: a market model for the raise, a continuous read for the competitive set. Companies that already subscribe sometimes add Prognyx precisely because the platform was never meant to be the thing that notices a competitor's completion date slipping.
How to decide in one question
Ask whether your open question has a number for an answer or a name. If it needs a number — market size, patient population, approval odds — buy the research platform. If it needs a name and a date, buy the watch.
Comparison last reviewed 1 September 2026. This page describes GlobalData from its public product information and does not claim to be exhaustive; GlobalData does not publish list pricing, and nothing here invents any. Prognyx has no affiliation with GlobalData. Verify current scope and pricing with the vendor directly before any purchase decision. Names and trademarks referenced belong to their owners.
Frequently asked
What is the best GlobalData alternative for a small biotech?
If you need epidemiology, forecasting or pricing intelligence, the alternatives are other research houses — those are dataset and modelling capabilities. If what you need is somebody watching your oncology competitive set and telling you what changed, that is a delivered service: Prognyx does it from $2,000/mo, with every claim traced to a primary source.
Does Prognyx do market forecasting or epidemiology?
No. Prognyx does not model patient populations, forecast revenue, or produce market sizing. It reads a competitive landscape and says what a competitor’s move means for your asset. If you need a market model, buy one.
Is Prognyx cheaper than GlobalData?
GlobalData does not publish list pricing, so an honest direct comparison is not possible and this page will not fabricate one. Prognyx publishes its floor at $2,000/mo. They are also not substitutes: one sells market research and data access, the other sells a continuous read.
Does Prognyx use GlobalData data?
No. Prognyx holds no paid-database licence and works only from primary public records, each cited so you can open it. See how we work.
Judge it on a brief, not a demo.
Name one asset you'd want watched. You get a real competitive brief on it — free, sourced, no obligation.
Request a sample brief → Compare with Cortellis